Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))
Publication date
2013-02-01
Authors
Albanesi, Marcello
Mancardi, David A.
Macdonald, Lynn E.
Iannascoli, Bruno
Zitvogel, Laurence
Murphy, Andrew J.
Daëron, Marc
Leusen, Jeanette H.W.
Bruhns, Pierre
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
Abstract
Keywords
Immunology and Allergy, Immunology
Citation
Albanesi, M, Mancardi, D A, Macdonald, L E, Iannascoli, B, Zitvogel, L, Murphy, A J, Daëron, M, Leusen, J H & Bruhns, P 2013, 'Erratum : Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))', Journal of Immunology, vol. 190, no. 3, pp. 1381. https://doi.org/10.4049/jimmunol.1290083